The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against ... process with no greater ...

All participants had received stroke care at hospitals within multiple health systems in Minnesota or Wisconsin. Researchers assessed outcomes for people who were prescribed either a GLP-1 or an SGLT2 ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

Semaglutide remains on the agency’s drug shortage list, but all FDA-approved forms of the drug are no longer ... In October, ...

all-natural supplement formulated to address pervasive gut-related side effects of glucagon-like peptide 1 (GLP-1) medications, including popular weight-loss drugs like Ozempic ®, Wegovy ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

However, retained gastric contents were not a problem in a subset of patients taking GLP-1 drugs who had been on ... with early-stage disease in nearly all cases. Risk factors in younger patients ...

more people are going to be on new versions of these drugs, all over the planet,” he said. As GLP-1 drugs increase in prevalence, the food industry is responding by aiming to give consumers what they ...